Noteworthy Rating Filing: MediWound Ltd (NASDAQ:MDWD) Hit With Buy Rating At Aegis Capital, Firm Sees $11.00 Stock Price

November 28, 2016 - By Winifred Garcia

Noteworthy Rating Filing: MediWound Ltd (NASDAQ:MDWD) Hit With Buy Rating At Aegis Capital, Firm Sees $11.00 Stock Price

Why Aegis Capital Gives MediWound Ltd (NASDAQ:MDWD) $11.00 Price Target

New York: MediWound Ltd (NASDAQ:MDWD) coverage was was started with a Buy rating and $11.00 price target at Aegis Capital. Aegis Capital’s TP indicates upside of 103.70% from the company’s previous stock close.

Mediwound Ltd (NASDAQ:MDWD) Ratings Coverage

Out of 4 analysts covering MediWound (NASDAQ:MDWD), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $15 is the highest target while $13 is the lowest. The $14 average target is 159.26% above today’s ($5.4) stock price. MediWound has been the topic of 4 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Credit Suisse on Monday, August 10. The stock of Mediwound Ltd (NASDAQ:MDWD) has “Buy” rating given on Wednesday, March 23 by SunTrust. Wells Fargo initiated Mediwound Ltd (NASDAQ:MDWD) on Wednesday, August 17 with “Outperform” rating.

About 22,095 shares traded hands or 10.96% up from the average. Mediwound Ltd (NASDAQ:MDWD) has declined 37.80% since April 25, 2016 and is downtrending. It has underperformed by 43.81% the S&P500.

Analysts await Mediwound Ltd (NASDAQ:MDWD) to report earnings on January, 23. They expect $-0.25 earnings per share, up 30.56% or $0.11 from last year’s $-0.36 per share. After $-0.26 actual earnings per share reported by Mediwound Ltd for the previous quarter, Wall Street now forecasts -3.85% EPS growth.

MediWound Ltd. is a biopharmaceutical firm focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The company has a market cap of $124.01 million. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. It currently has negative earnings. NexoBrid is based on the Company’s proteolytic enzyme technology.

According to Zacks Investment Research, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel.”

MDWD Company Profile

MediWound Ltd., Incorporated on January 27, 2000, is a biopharmaceutical firm focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. NexoBrid is based on the Company’s proteolytic enzyme technology. It offers NexoBrid in Europe and Israel.

Another recent and important Mediwound Ltd (NASDAQ:MDWD) news was published by Marketwatch.com which published an article titled: “/quotes/zigman/3870025/realtime” on March 21, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>